Dosing & Uses
Dosage Forms & Strengths
irrigation solution
- 3g/100mL (3%)
oral solution
- 70%
Constipation
Oral: 30-150 mL (70% solution) once
Rectal enema: 120 mL of 25-30% solution once
Sodium Polystyrene Sulfonate Adjunct
15 mL of 70% solution or 10-20 mL/2 hours PO until diarrhea occurs
Transurethral Surgical Procedures
3-3.3% as surgical procedure irrigation
Dosage Forms & Strengths
irrigation solution
- 3g/100mL (3%)
oral solution
- 70%
Constipation
< 2 years
- Safety & efficacy not established
2-11 years
- Oral: 2 mL/kg (as 70% solution) once
- Rectal enema: 30-60 mL as 25-30% solution
≥12 years
- Oral: 30-150 mL (70% solution) once
- Rectal enema: 120 mL of 25-30% solution once
Sodium Polystyrene Sulfonate Adjunct
<12 years: Safety & efficacy not established
≥12 years: 15 mL of 70% solution or 10-20 mL/2 hours PO until diarrhea occurs
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (2)
- lamivudine
sorbitol will decrease the level or effect of lamivudine by Other (see comment). Avoid or Use Alternate Drug. Sorbitol-containing solution decreased systemic exposure of lamivudine oral solution in a pediatric study (ARROW trial). Results showed lower rates of virologic suppression, lower plasma lamivudine exposure, and development of viral resistance more frequently than children receiving lamivudine tablets.
- sodium polystyrene sulfonate
sodium polystyrene sulfonate, sorbitol. Mechanism: unknown. Avoid or Use Alternate Drug. Combination implicated in cases of colonic necrosis.
Monitor Closely (2)
- deflazacort
sorbitol and deflazacort both decrease serum potassium. Use Caution/Monitor.
- dichlorphenamide
dichlorphenamide, sorbitol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
Minor (0)
Adverse Effects
Frequency Not Defined
Excessive bowel activity
Diarrhea
Edema
Dehydration
Fluid and electrolyte losses
Hyperglycemia
Lactic acidosis
Dry mouth
Xerostomia
Vomiting
Abdominal discomfort
Nausea
Warnings
Contraindications
Anuria, acute abdominal pain, nausea, vomiting, or other symptoms of appendicitis or undiagnosed abdominal pain
Cautions
Patients with severe cardiopulmonary or renal impairment
Dehydration, electrolyte abnormalities
Patients unable to metabolize sorbitol
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Polyalcoholic sugar with hyperosmotic effects that induces catharsis
Pharmacokinetics
Onset: 0.25-1 hr
Absorption: Poor (oral and rectal)
Metabolism: Mainly in the liver to fructose
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
